Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets

Table 1 (a) Top upregulated and (b) top down-regulated DEGs in vitiligo (VL)-blood expression profile

Entrez ID	Gene Symbol	Gene Title	p-value	Fold-Change
a
2201	FBN2	fibrillin 2	0.0345	1.5
1577	CYP3A5	cytochrome P450, family 3, subfamily A, polypeptide 5	0.0315	1.5
23253	ANKRD12	ankyrin repeat domain 12	0.0236	1.4
1545	CYP1B1	cytochrome P450, family 1, subfamily B, polypeptide 1	0.0069	1.4
b
9636	ISG15	ISG15 ubiquitin-like modifier	0.0172	−4.2
3434	IFIT1	interferon-induced protein with tetratricopeptide repeats 1	0.0168	−4.0
710	SERPING1	serpin peptidase inhibitor, clade G (C1 inhibitor), member 1	0.008	−4.0
10964	IFI44L	interferon-induced protein 44-like	0.0283	−3.6
4599	MX1	myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse)	0.0098	−3.5
3437	IFIT3	interferon-induced protein with tetratricopeptide repeats 3	0.0133	−3.5
4277	MICB	MHC class I polypeptide-related sequence B	0.0085	−3.3
653361///654816///654817	NCF1///NCF1B///NCF1C	neutrophil cytosolic factor 1///neutrophil cytosolic factor 1B pseudogene///neutrophil	0.0436	−2.7
8638	OASL	2′-5′-oligoadenylate synthetase-like	0.0334	−2.7
10581	IFITM2	interferon induced transmembrane protein 2	0.0342	−2.7

Fold Change; a “positive” fold change indicates an upregulation and a “negative” fold change indicates a down-regulation in peripheral blood of VL patients vs. healthy controls

ISSN: 1471-2164